Fullerenes, the soccer ball-shaped spheres of carbon that helped usher in the nanotechnology era, have been touted as versatile containers for delivering drugs and other clinically useful molecules to tumors. Turning promise into reality, investigators from the National Cancer Institute’s Cancer Nanotechnology Platform Partnership at Virginia Commonwealth University have developed a new imaging agent that is 40 times more potent at boosting magnetic resonance imaging (MRI) signals than agents currently approved for human clinical use.